It’s only fair to share… Nibrozetone CAS 925206-65-1 MF C5H6BrN3O5 MW268.02 g/mol 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethan-1-one 2-Bromo-1-(3,3-dinitroazetidin-1-yl)ethanone 2-BROMO-1-(3,3-DINITROAZETIDIN-1-YL)ETHAN-1-ONE anti-inflammatory, RRx-001, RRx 001, ABDNAZ Nibrozetone is an investigational new drug that is being evaluated by EpicentRx for the treatment of oral mucositis in head and neck cancer patients. It is a small molecule that combines direct inhibition of the NLRP3 inflammasome, induction of NRF2, and release of nitric oxide under hypoxic conditions.[1][2] It has received Fast Track designation from …
Neladalkib
It’s only fair to share… Neladalkib CAS 2739866-40-9 MF C23H22ClFN6O MW 452.9 g/mol (19R)-5-chloro-3-ethyl-16-fluoro-10,19-dimethyl-20-oxa-3,4,10,11,23-pentazapentacyclo[19.3.1.02,6.08,12.013,18]pentacosa-1(25),2(6),4,8,11,13(18),14,16,21,23-decaen-22-amine anaplastic lymphoma kinase (ALK) inhibitor, antineoplastic, NVL-655, NVL 655, J32P26A6BC, ALK-IN-27 Neladalkib is a small molecule drug. The usage of the INN stem ‘-alkib’ in the name indicates that Neladalkib is a ALK (anaplastic lymphoma kinase) inhibitor. Neladalkib is under investigation in …
Nefextinib
It’s only fair to share… Nefextinib CAS 2070931-57-4 MF C22H23FN6OS MW 438.52 7-(4-fluoro-2-methoxyphenyl)-6-methyl-N-[1-(piperidin4-yl)-1H-pyrazol-4-yl]thieno[3,2-d]pyrimidin-2-amine 7-(4-FLUORO-2-METHOXYPHENYL)-6-METHYL-N-(1-(PIPERIDIN-4-YL)-1H-PYRAZOL-4-YL) THIENO (3,2-D)PYRIMIDIN-2-AMINEtyrosine kinase inhibitor, antineoplastic, DL772G3NN7, MAX-40279, MAX 40279 Nefextinib is an orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) and FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential antineoplastic activity. Upon oral administration, nefextinib binds to and inhibits both …
Muvadenant
It’s only fair to share… Muvadenant CAS 2459881-03-7 MF C21H26N4O4S , 430.5 g/mol (5S)-N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy[1,3]thiazolo[4,5-c]pyridin-2-yl]-7-oxa-2-azaspiro[4.5] decane-2-carboxamide (5S)-N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-7-oxa-2-azaspiro[4.5]decane-2-carboxamideadenosine receptor antagonist, antineoplastic, 6LSF69F6A8, M1069 , M 1069 Muvadenant is a small molecule drug. The usage of the INN stem ‘-adenant’ in the name indicates that Muvadenant is a adenosin receptor antagonist. Muvadenant has a monoisotopic molecular weight of 430.17 Da. …
Matsupexole
It’s only fair to share… Matsupexole CAS 1399442-97-7 MF C22H34N6O2S, Molecular Weight, 446.61 (4aR,6R,8aR)-2-amino-3-cyano-N-{[2-(dimethylamino)ethyl]carbamoyl}-8-methyl-N-propyl 4,4a,5,6,7,8,8a,9-octahydrothieno[3,2-g]quinoline-6-carboxamide (4aR,6R,8aR)-2-amino-3-cyano-N-[2-(dimethylamino)ethylcarbamoyl]-8-methyl-N-propyl-4a,5,6,7,8a,9-hexahydro-4H-thieno[3,2-g]quinoline-6-carboxamidedopamine receptor agonist, Phase 2, Parkinson’s disease, K4UEG65HTX PAT SYN WO-2022009815-A1 https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2022009815&_cid=P22-MHO952-66657-1 [0018]Example 11-{[(4aR,6R,8aR)-2-amino-3-cyano-8-methyl-4,4a,5,6,7,8,8a,9-octahydrothieno[3,2-g]quinolin-6-yl]carbonyl}-3-[2-(dimethylamino)ethyl]-1-propylurea sesquisuccinate monohydrate (Form I crystals of salt (A-1)) 102.8 g of acetone was added to 1-{[(4aR,6R,8aR)-2-amino-3-cyano-8-methyl-4,4a,5,6,7,8,8a,9-octahydrothieno[3,2-g]quinolin-6-yl]carbonyl}-3-[2-(dimethylamino)ethyl]-1-propylurea (22.00 g), the mixture was suspended, and the suspension was heated …
Mangaciclanol
It’s only fair to share… Mangaciclanol Cas 2169771-05-3 MF C34H56MnN6O16 MW859.8 g/mol 2-[9-[1-carboxylato-4-oxo-4-[[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl]amino]butyl]-6-methyl-3,6,9,15-tetrazabicyclo[9.3.1]pentadeca-1(15),11,13-trien-3-yl]-5-oxo-5-[[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl]amino]pentanoate;manganese(2+) diagnostic imaging agent, ANU6AE7NAP AS ON OCT2025 4.511 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT join me on Linkedin Anthony Melvin Crasto Ph.D – India | LinkedIn join me on Researchgate RESEARCHGATE join me on Facebook Anthony Melvin Crasto Dr. | Facebook join me on twitter …
Elinzanetant
It’s only fair to share… Elinzanetant CAS 929046-33-3 MW 668.6 g/mol MF C33H35F7N4O3 N-[6-[(7S,9aS)-7-(hydroxymethyl)-3,4,6,7,9,9a-hexahydro-1H-pyrazino[2,1-c][1,4]oxazin-8-yl]-4-(4-fluoro-2-methylphenyl)-3-pyridinyl]-2-[3,5-bis(trifluoromethyl)phenyl]-N,2-dimethylpropanamide FDA 10/24/2025, Lynkuet, To treat moderate-to-severe vasomotor symptoms due to menopause BAY-3427080; GSK-1144814; NT-814, UNII-NZW2BOW35N Elinzanetant, sold under the brand name Lynkuet, is a medication used for the treatment of moderate to severe vasomotor symptoms due to menopause.[4] It is an neurokinin 1 and neurokinin 3 receptor antagonist.[4] It was developed by Bayer …
Lunresertib
It’s only fair to share… Lunresertib CAS 2719793-90-3 MF C18H20N4O2 MW 324.4 g/mol (1P)-2-amino-1-(3-hydroxy-2,6-dimethylphenyl)-5,6-dimethyl1H-pyrrolo[2,3-b]pyridine-3-carboxamideserine/ threonine kinase inhibitor, antineoplastic, N95U3A7N57, RP-6306, RP 6306 2-Amino-1-(3-hydroxy-2,6-dimethylphenyl)-5,6-dimethylpyrrolo[2,3-b]pyridine-3-carboxamide Lunresertib is an investigational new drug that is being evaluated for the treatment of cancer. It is an oral small molecule inhibitor of PKMYT1, developed by Repare Therapeutics.[1] This drug targets cell cycle regulation in tumors with specific …
Lunbotinib
It’s only fair to share… Lunbotinib CAS 2479961-46-9 MF C28H28FN11 MW537.6 g/mol 2-[6-(6-{[6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl]methyl}-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl]-6-methyl-N-(5-methyl1H-pyrazol-3-yl)pyrimidin-4-aminetyrosine kinase inhibitor, antineoplastic, KL3T9ZU6HQ Lunbotinib is an orally bioavailable selective inhibitor of the proto-oncogene receptor tyrosine kinase rearranged during transfection (RET), with potential antineoplastic activity. Upon oral administration, lunbotinib selectively binds to various RET fusions and mutations, including solvent front resistance mutations, and inhibits the …
Lomedeucitinib
It’s only fair to share… Lomedeucitinib CAS 2328068-29-5 MF C18H172H3N6O4S MW 419.5 g/mol 4-{[3-(methanesulfonyl)pyridin-2-yl]amino}-N-(2H3)methyl-6-[(1R)-spiro[2.2]pentane-1-carboxamido]pyridazine-3-carboxamide 4-[(3-methylsulfonyl-2-pyridinyl)amino]-6-[[(2R)-spiro[2.2]pentane-2-carbonyl]amino]-N-(trideuteriomethyl)pyridazine-3-carboxamideJanus kinase inhibitor, anti-inflammatory, BMS-986322, BMS 986322, EYQ7KA55XA Lomedeucitinib is an investigational new drug that is being evaluated for the treatment of psoriasis and psoriatic arthritis. It is a tyrosine kinase 2 (TYK2) inhibitor.[1] SYN US20210253554 https://patentscope.wipo.int/search/en/detail.jsf?docId=US333829535&_cid=P10-MHIXWK-98212-1 General Scheme for Examples 252 and 253: Example 252 Step 1 A mixture …